Transcatheter Arterial Infusion Combined With Radioactive Particles in the Treatment of Advanced Body/Tail Pancreatic Cancer A Retrospective Cohort Study
Transcatheter Arterial Infusion Combined With Radioactive Particles in the Treatment of Advanced Body/Tail Pancreatic Cancer A Retrospective Cohort Study
复制标题
经导管动脉灌注联合放射性粒子治疗晚期体尾胰腺癌的回顾性队列研究
DOI：
10.1097/mpa.0000000000001851
复制
发表时间：
2021
期刊：
影响因子：
2.9
通讯作者：
Zhang Xiaoping
中科院分区：
文献类型：
--
作者：
Han Shilong;Cao Chuanwu;Yuan Yifeng;Chen Jun;Yin Linan;Xu Huirong;Liu Jingzhou;Wang Wujie;Li Yuliang;Wang Lizhou;Zhou Shi;Li Fenqiang;Wang Wenhui;Ji Jiansong;Long Haideng;Yin Shiwu;Li Jue;Han Jianjun;Liu Ruibao;Li Maoquan;Zhang Xiaoping
目的本回顾性队列研究通过评估短期和总生存率，探讨常规静脉化疗（对照组）、经导管动脉灌注（TAI）化疗以及TAI联合放射性粒子治疗晚期体/尾胰腺癌的疗效。方法我们对晚期体/尾胰腺癌患者的前瞻性数据库进行筛选。 胰腺癌，肿瘤被认为无法切除，并且没有其他确诊的恶性肿瘤，根据治疗情况将患者分为3组：常规静脉化疗、TAI、TAI联合放射性粒子。结果对照组中位生存时间为6个月，TAI组为10个月，TAI联合组为13个月。 Kaplan-Meier估计3组之间的总生存率，表明3组之间存在显着差异（P<0.000）。对照组的临床缓解率为17.5%，TAI组为41.5%，TAI联合组为48.0%。协变量分析显示，不同的治疗方法和时间对结果影响显着（P<0.002）。结论在晚期体尾胰腺癌的治疗中，与常规静脉化疗相比，TAI和TAI联合放射性粒子显着改善患者的临床结局。
ObjectivesThis retrospective cohort study investigated the efficacy of routine intravenous chemotherapy (the control group), transcatheter arterial infusion (TAI) chemotherapy, and TAI combined with radioactive particles as therapeutic methods for advanced body/tail pancreatic cancer by assessing the short-term and overall survival rates.MethodsWe screened our prospective database for patients with advanced body/tail pancreatic cancer, which tumor deemed unresectable, and no other confirmed malignant tumors, patients were assigned into 3 groups according to their treatment: routine intravenous chemotherapy, TAI, and TAI combined with radioactive particles.ResultsThe median survival time was 6 months in the control group, 10 months in the TAI group, and 13 months in the TAI combined group. The Kaplan-Meier estimates of the overall survival among the 3 groups, indicating that there is significant difference among 3 groups (P< 0.000). The clinical remission rates were 17.5% in the control group, 41.5% in the TAI group, and 48.0% in the TAI combined group. Covariates analyzed showed that different treatment methods and times affected the results significantly (P< 0.002).ConclusionsIn the treatment of advanced body/tail pancreatic cancer, TAI and TAI combined with radioactive particles significantly improved the clinical outcomes in patients compared with routine intravenous chemotherapy.